Treats Manic and Mixed Episodes associated with Bipolar I Disorder Irritability…. ANDA 204171, held by Lannett Co Inc. Aripiprazole.
As of Nov 16, 2026, ANDA 204171 (Aripiprazole), held by Lannett Co Inc, was first approved by FDA on Aug 14, 2015, with 7 approved supplements and 0 published complete response letters.
Aripiprazole Oral Solution is indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Irritability Associated with Autistic Disorder Treatment of Tourette’s disorder
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 14, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Aripiprazole1MG/ML · solution;oral | Aripiprazole | Rx |
| Jan 24, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Jan 23, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jan 23, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Feb 5, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 6, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 18, 2016 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 14, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters